Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioKALA +3.06%21 3-Year EBITDA Growth Rate is 51.20% as of Jun. 2026, which is 74% above its 10-year median of 29.45. GuruFocus rates KALA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Kala Bio ranks better than 86.51% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 51.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 51.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 26.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kala Bio was 56.30% per year. The lowest was -36.60% per year. And the median was 29.45% per year.
Kala Bio (NAS:KALA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kala Bio 3-Year EBITDA Growth Rate Related Terms
KALA vs GTBP, PHIO, ICU: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Kala Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Kala Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 51.20% mean?
Kala Bio (KALA) has a 3-Year EBITDA Growth Rate of 51.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kala Bio and its competitors. This is 74% above median its historical median of 29.45. According to the industry distribution chart, Kala Bio ranks #152 out of 1127 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Kala Bio's 3-Year EBITDA Growth Rate too high?
Kala Bio's current 3-Year EBITDA Growth Rate of 51.20% is 74% above median its 10-year median of 29.45. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Kala Bio's value of 51.20% is 250.7% above this industry median. Based on the distribution chart, Kala Bio ranks #152 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kala Bio has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's 3-Year EBITDA Growth Rate compare to GTBP and PHIO?
According to the Biotechnology industry distribution chart, Kala Bio ranks #152 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Kala Bio in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Kala Bio's value of 51.20% is 250.7% above this benchmark. While the company's 10-year median is 29.45 vs. the industry median of 14.60, Kala Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kala Bio's current 3-Year EBITDA Growth Rate of 51.20% is 250.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kala Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current 3-Year EBITDA Growth Rate is 51.20%, which is 74% above median its own 10-year median of 29.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (KALA) has a current 3-Year EBITDA Growth Rate of 51.20%. The current 3-Year EBITDA Growth Rate is 51.20%, which is 74% above median its 10-year median of 29.45 and 250.7% above the Biotechnology industry median of 14.60. Kala Bio's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kala Bio (KALA), the current 3-Year EBITDA Growth Rate is 51.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
21GF Score
Get the complete analysis for KALA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KALA has been successfully added to your 
